‘Les liaisons dangereuses’: Hepatitis C, Rituximab and B-cell non-Hodgkin’s lymphomas  

作　　者：Massimo Marignani Michela di Fonzo Paola Begini Elia Gigante Ilaria Deli Adriano M Pellicelli Sara Gallina Emanuela de Santis Gianfranco Delle Fave M Christina Cox 

机构地区：[1]Department of Digestive and Liver Disease, School of Medicine and Psychology University "Sapienza", Azienda Ospedaliera S. Andrea, Via Grottarossa, 1035-1039, 00189 Rome, Italy [2]Liver Unit, Azienda Ospedaliera San Camillo Forlanini, 000149 Rome, Italy [3]Department of Haematology, School of Medicine and Psychology University "Sapienza" Azienda Ospedaliera S. Andrea, Via Grottarossa, 1035-1039, 00189 Rome, Italy

出　　处：《World Journal of Gastrointestinal Pharmacology and Therapeutics》2012年第2期21-28,共8页世界胃肠药理与治疗学杂志（英文版）（电子版）

摘　　要：Rituximab has provided a revolutionary contribution to the treatment of B-cell non-Hodgkin’s lymphomas (NHL). A high prevalence of hepatitis C virus (HCV) infection has been described in B-cell NHL patients. Cases of liver dysfunction in HCV-positive patients have been reported with Rituximab-containing regimens. In this paper we review the recent data regarding the effects of Rituximab in NHL patients with HCV infection. We also added a section devoted to improving communication between oncohaematologists and hepatologists. Furthermore, we propose a common methodological ground to study hepatic toxicity emerging during chemotherapy.Rituximab has provided a revolutionary contribution to the treatment of B-cell non-Hodgkin’s lymphomas (NHL). A high prevalence of hepatitis C virus (HCV) infection has been described in B-cell NHL patients. Cases of liver dysfunction in HCV-positive patients have been reported with Rituximab-containing regimens. In this paper we review the recent data regarding the effects of Rituximab in NHL patients with HCV infection. We also added a section devoted to improving communication between oncohaematologists and hepatologists. Furthermore, we propose a common methodological ground to study hepatic toxicity emerging during chemotherapy.

关 键 词：RITUXIMAB B-CELL non-Hodgkin’s LYMPHOMA Hepatitis C virus IMMUNOCHEMOTHERAPY Methodology 

分 类 号：R733.1[医药卫生—肿瘤]